Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/dinto_DB04832
http://purl.obolibrary.org/obo/dinto_DB04832
|
|---|---|
| Preferred Name | zimelidine |
| Synonyms |
C16H17BrN2
[3-(4-bromophenyl)-3-(pyridin-3-yl)prop-2-en-1-yl]dimethylamine
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | zimelidine
|
|---|---|
| label | zimelidine
|
| DBSynonym |
(z)-3-[1-(p-bromophenyl)-3-(dimethylamino)propenyl]pyridine
(z)-zimelidine
cis-zimelidine
(z)-3-(4'-bromophenyl)-3-(3''-pyridyl)dimethylallylamine
zimeldine
|
| ATCCode | N06AB02
|
| Definition | Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barr? syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exanthema, flu-like symptoms, arthralgias, and sometimes eosinophilia. Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients. After its ban, it was succeeded by fluvoxamine and fluoxetine (derived from the antihistamine diphenhydramine) in that order, and the other SSRIs.
|
| inhibits | |
| type | |
| InChIKey | InChIKey=OYPPVKRFBIWMSX-SXGWCWSVSA-N
|
| Synonym |
C16H17BrN2
[3-(4-bromophenyl)-3-(pyridin-3-yl)prop-2-en-1-yl]dimethylamine
|
| xref |
Wikipedia:http://en.wikipedia.org/wiki/Zimelidine
PubChem Substance:46504589
ChemSpider:38293
PubChem Compound:5365247
|
| CASRN | 56775-88-3
|
| prefixIRI | obo2:dinto_DB04832
|
| related with | |
| SMILES | CN(C)CC=C(C1=CC=C(Br)C=C1)C1=CN=CC=C1
|
| InChI | InChI=1S/C16H17BrN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-10,12H,11H2,1-2H3/b16-9-
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |